Treatment and prevention of venous thromboembolic complications: focus on sulodexide

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Venous thromboembolic complications (VTEC) are a common pathology that includes pulmonary embolism and deep vein thrombosis of the lower extremities. Modern drug therapy for VTEC includes taking anticoagulants, which reduce the risk of VTEC recurrence to 1–2% of cases. The article discusses the drug sulodexide, which belongs to the class of heparinoids. Sulodexide is a relatively safe drug that has anti-inflammatory and antithrombotic effects, reducing the release of cytokines, chemokines and growth factors, as well as proteinases and degrading enzymes. When taken orally, there is no pharmacological interaction with substances aimed at treating vascular diseases, so it can be prescribed to patients with concomitant diseases.

全文:

受限制的访问

作者简介

I. Rodionova

Volgograd State Medical University, Ministry of Health of Russia

编辑信件的主要联系方式.
Email: vskvortsov1@ya.ru

Candidate of Medical Sciences

俄罗斯联邦, Volgograd

M. Vinogradova

Volgograd State Medical University, Ministry of Health of Russia

Email: vskvortsov1@ya.ru
俄罗斯联邦, Volgograd

E. Skvortsova

Volgograd State Medical University, Ministry of Health of Russia

Email: vskvortsov1@ya.ru
俄罗斯联邦, Volgograd

V. Skvortsov

Volgograd State Medical University, Ministry of Health of Russia

Email: vskvortsov1@ya.ru
ORCID iD: 0000-0002-2164-3537

MD, Professor

俄罗斯联邦, Volgograd

参考

  1. Никулина Н.Н., Тереховская Ю.В. Эпидемиология тромбоэмболии легочной артерии в современном мире: анализ заболеваемости, смертности и проблем их изучения. Российский кардиологический журнал. 2019; 24 (6): 103–8 [Nikulina N.N., Terekhovskaya Yu.V. Epidemiology of pulmonary embolism in today’s context: analysis of incidence, mortality and problems of their study. Russian Journal of Cardiology. 2019; 24 (6): 103–8 (in Russ.)]. doi: 10.15829/1560-4071-2019-6-103-108
  2. Лобастов К.В., Навасардян А.Р., Счастливцев И.В. Вторичная профилактика венозных тромбоэмболических осложнений в реальной клинической практике по данным анкетирования врачей. Рациональная фармакотерапия в кардиологии. 2021; 17 (2): 376–85 [Lobastov K.V., Navasardyan A.R., Schastlivtsev I.V. Treatment and Secondary Prevention of Venous Thromboembolism in Real Clinical Practice Based on Health Care Professional Survey. Rational Pharmacotherapy in Cardiology. 2021; 17 (2): 376–85. (in Russ.)]. doi: 10.20996/1819-6446-2021-06-01
  3. Богачев В.Ю., Болдин Б.В., Дженина О.В. и др. Вторичная профилактика венозных тромбоэмболических осложнений. В фокусе – дабигатран. Амбулаторная хирургия. 2017; 3-4: 36–42 [Bogachev V., Boldin B.V., Djenina О., Lobanov V.N. Secondary prevention of venous thromboembolic complications. Focus on dabigatrane. Ambulatory Surgery (Russia). 2017; 3-4: 36–42 (in Russ.)].
  4. Стойко Ю.М., Карташева Е.Д. Выбор антикоагулянта у пациента с венозными тромбоэмболическими осложнениями. Амбулаторная хирургия. 2016; 1-2: 29–35 [Stoyko Yu.M., Kartasheva E.D. Choosing an anticoagulant for a patient with venous thromboembolic complications. Ambulatory Surgery (Russia). 2016; 1-2: 29–35 (in Russ.)].
  5. Линчак Р.М. Нюансы и алгоритмы антикоагулянтной терапии венозных тромбоэмболических осложнений на всех этапах лечения. Позиции апиксабана. Атмосфера. Новости кардиологии. 2020; 2: 26–36 [Linchak R.M. Details and Algorithms of Anticoagulant Therapy of Venous Thromboembolic Complications at All Stages of Treatment. Positions of Apixaban. Atmosfera. Novosti kardiologii. 2020; 2: 26–36 (in Russ.)].
  6. Veraldi N., Guerrini M., Urso E. et al. Fine structural characterization of sulodexide. J Pharm Biomed Anal. 2018; 156: 67–79. doi: 10.1016/j.jpba.2018.04.012
  7. Ligi D., Croce L., Mosti G. et al. Chronic venous insufficiency: transforming growth factor-beta isoforms and soluble endoglin concentration in different states of wound healing. Int J Mol Sci. 2017; 18: E2206. doi: 10.3390/ijms18102206
  8. Мясников Р.П., Куликова О.В., Харлап М.С. и др. Некомпактный миокард левого желудочка: вторичная профилактика тромбоэмболических осложнений. Кардиоваскулярная терапия и профилактика. 2017; 16 (1): 100–4 [Myasnikov R.P., Kulikova О.V., Kharlap М.S. et al. Non-compaction myocardium of the left ventricle: secondary prevention of thromboembolism. Cardiovascular Therapy and Prevention. 2017; 16 (1): 100–4 (in Russ.)]. doi: 10.15829/1728-8800-2017-1-100-104
  9. Zhang X., Sun D., Song J.W., et al. Endothelial cell dysfunction and glycocalyx – a viscious circle. Matrix Biol. 2018; 72: 421–31. doi: 10.1016/j.matbio.2018.01.026
  10. Поляков А.С., Тыренко В.В., Крюков Е.В. и др. Оптимальный выбор антикоагулянтной профилактики при неклапанной фибриляции предсердий в период пандемии COVID-19. Российский кардиологический журнал. 2021; 26 (8): 4607 [Polyakov A.S., Tyrenko V. V., Kryukov E.V. et al. Optimal choice of prophylactic anticoagulant therapy for nonvalvular atrial fibrillation in the context of COVID-19 pandemic. Russian Journal of Cardiology. 2021; 26 (8): 4607 (in Russ.)]. doi: 10.15829/1560-4071-2021-4607
  11. Kearon C., Akl E., Ornelas J. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149 (2): 315–52. doi: 10.1016/j.chest.2015.11.026
  12. Ширинбек О. Фармакотерапия хронических заболеваний вен: возможности сулодексида. Амбулаторная хирургия. 2015; 1-2: 26–30 [Shirinbek O. Pharmacotherapy of chronic vein diseases: possibilities of sulodexide. Ambulatory Surgery (Russia). 2015; 1-2: 26–30 (in Russ.)].
  13. Воробьев П.А., Воробьев А.П., Краснова Л.С. и др. Систематический обзор по оценке медицинской технологии применения лекарственного препарата Вессел Дуэ ф для лечения тромботических заболеваний вен. Проблемы стандартизации в здравоохранении. 2016; 7-8: 61–6 [Vorobiev P.A., Vorobiev A.P., Krasnova L.S. et al. Systematic review on health technology assessment of the use of drugs vessel due f for treatment of thrombotic diseases of the veins. Problems of standardization in healthcare. 2016; 7-8: 61–6 (in Russ.)].
  14. Iafrati M.D. Medical therapies for chronic venous insufficiency. In book: Venous Ulcers (Second Edition). Akademic Press,2023; pp. 261–82. doi: 10.1016/B978-0-323-90610-4.00010-0
  15. Lasierra Cirujeda J., Coronel Granado P. A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology. 2006; 57 (1): 53–64. doi: 10.1177/000331970605700108
  16. Coccheri S, Scondotto G, Agnelli G, et al. Randomized, double-blind, multicentre, placebo-controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost. 2002; 87 (6): 947–52.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2024
##common.cookie##